What this is
- This research evaluates the impact of maternal obesity on myometrial contractility and receptor expression during pregnancy.
- It focuses on individuals with a body mass index (BMI) of 30 kg/m or higher compared to those with a BMI under 25 kg/m.
- The study aims to clarify the biological mechanisms behind higher cesarean rates and labor complications linked to obesity.
Essence
- Maternal obesity does not affect myometrial contractility or the expression of oxytocin and prostaglandin receptors compared to normal-weight individuals. This suggests alternative mechanisms may underlie the higher rates of labor dysfunction seen in obese pregnant individuals.
Key takeaways
- Myometrial contractility parameters, including frequency and force of contractions, showed no significant differences between obese and normal-weight pregnant individuals. This finding contradicts previous studies that suggested obesity negatively impacts myometrial function.
- Both oxytocin and prostaglandin receptor expressions were similar in myometrial samples from obese and normal-weight individuals. While FP gene expression was lower in the obese group, protein levels did not differ, indicating complex interactions may be at play.
Caveats
- The study's sample size for contractility experiments was small, limiting the generalizability of the findings. Only a subset of participants had usable samples for contractility analysis.
- Samples were collected from individuals undergoing cesarean delivery, which may not reflect myometrial function during active labor. This could affect the interpretation of contractility results.
AI simplified
Introduction
Obesity (body mass index, BMI \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\ge$$\end{document}≥ 30 kg/m2) is a serious and growing public health problem. In the United States, it is estimated that almost one third of pregnant individuals have obesity [1]. Pregnant individuals with obesity experience higher rates of obstetric complications, such as hypertensive disorders [2, 3] and gestational diabetes mellitus, compared to individuals with normal weight (BMI 18.5–24.9 kg/m2) [4, 5]. In addition, obesity is a risk factor for fetal macrosomia and adverse neonatal outcomes [5–7].
Individuals with obesity are also are more than twice as likely to deliver by cesarean compared with those of normal-weight, with cesarean rates as high as 50% in individuals with class III obesity (BMI \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\ge$$\end{document}≥ 40 kg/m2) [8–10]. In the United States, labor arrest is a leading indication for cesarean in all pregnant individuals, but a significantly higher proportion of cesarean deliveries in individuals with obesity are for this indication than for those with lower BMI [9]. Several studies evaluating labor curves have shown that increasing maternal BMI is associated with slower progression of cervical dilation in labor [11, 12]. Moreover, obesity increases the risk for post-operative complications among those who deliver by cesarean, including postpartum hemorrhage and infection [13–15]. The relationship between obesity in pregnancy and dysfunctional labor is well-established, however, a biological explanation has yet to be defined.
A leading hypothesis is that obesity directly affects intrinsic contractile properties within the myometrium, but the findings in prior studies evaluating contractility have been conflicting. In one of the first studies comparing in vitro myometrial contractility and maternal BMI, Zhang et al. [16] found that myometrial samples from individuals with obesity contracted less frequently and with less force than myometrial samples from those with normal weight. Follow up studies reported inconsistent association between obesity and contractile measures of myometrial tissue, such as frequency and time to onset of contractions [17, 18], while other investigators have failed to demonstrate an effect of obesity on myometrial contractile responses to oxytocin [19].
Further research on the biomolecular mechanisms by which obesity affects myometrial function is also needed. The neuropeptide oxytocin stimulates myometrial contractions through multiple pathways [20], but there is a paucity of data on the association between maternal BMI and oxytocin signaling. In a study of 20 individuals, Garbedian et al. found a positive correlation between myometrial expression of oxytocin receptor (OXTR) and maternal BMI [21], but in a slightly larger study Grotegut et al. [22] reported that neither OXTR gene or OXTR protein expression was affected by maternal BMI.
Therefore, we conducted this prospective cohort study to evaluate whether obesity in pregnancy is associated with reduced spontaneous and oxytocin-stimulated myometrial contractile activity using ex vivo preparations. We also examined the relationship between maternal obesity status and expression of oxytocin and prostaglandin F2α receptors (FP) in order to better understand differences in myometrial contractility at the molecular level. We hypothesized that myometrial tissue from term individuals with obesity have reduced expression of the OXTR and FP and decreased contractility compared with samples from normal-weight individuals.
Methods
Participant Enrollment
Pregnant individuals presenting to the labor and delivery unit at The Ohio State University Wexner Medical Center from March 2020 through March 2022 for scheduled cesarean delivery at term (≥ 37 weeks’ gestation) were approached for enrollment in this prospective study. Only individuals between the ages of 18–48 years with a singleton gestation and a pre-pregnancy BMI < 25.0 kg/m2 (normal BMI group) or pre-pregnancy BMI ≥ 30 kg/m2 were eligible. Individuals in labor at the time of cesarean delivery, including those with rupture of membranes and/or regular uterine contractions with cervical change were excluded. Patients with pre-existing (Type 1 or Type 2) diabetes mellitus were excluded to avoid potential metabolic confounding factors in muscle contractility experiments. Other exclusion criteria included oxytocin or prostaglandin use prior to cesarean delivery, magnesium sulfate exposure within 12 h prior to delivery, HIV, hepatitis B or hepatitis C virus or other sexually transmitted infections, suspected or confirmed chorioamnionitis, and abnormal placentation. Approval was obtained from the Ohio State University Biomedical Institutional Review Board prior to starting the study. All participants provided written informed consent.
Trained research staff collected clinical information from participants’ medical records following enrollment. This included information about maternal age, parity, race and ethnicity, gestational age, indication for cesarean and infant birthweight.
Myometrial Tissue Collection and Processing
Myometrial tissue samples measuring approximately 3.5 cm in length and 2 cm in height were excised from the upper edge of the hysterotomy incision immediately following delivery of the fetus and placenta. Specimens were processed within 12 h of collection. The specimens were stored at 4ºC in isotonic saline containing glucose and pyruvate until processing was completed. After dissecting decidua and serosa from the specimen, the myometrial tissue was rinsed with cold physiological saline solution (PSS, 154 mM NaCl, 5.6 mM KCl, 1.2 mM MgSO4, 7.8 mM glucose, 2 mM CaCl2, and 10.9 mM 2-[4-(2-hydroxyethyl)piperazin-1-1yl]ethanesulfonic acid, HEPES, pH 7.4) and cut into four to five ~ 2 × 8 × 1 mm strips to be used for contractility experiments. The muscle strips were placed in fresh, cold PSS for transport and storage. The remaining myometrial tissue was frozen immediately and stored at -80 °C for qRT-PCR and western blot analysis.
Reagents
Oxytocin was purchased from Tocris/BioTechne (Minneapolis, MN). Human recombinant interleukin-1β was purchased from R&D Systems (Minneapolis, MN). Protein assay reagent and bovine serum albumin (BSA) as standard, Precision Plus™ protein molecular weight standards, and Clarity™ chemiluminescent reagent were obtained from Biorad (Hercules, CA). All other chemicals were reagent grade and were purchased from Sigma/Aldrich (St. Louis, MO).
Myometrial Contractility Studies
Contractility experiments were completed within 16 h of cesarean delivery using the technique described by Arrowsmith et al. [23]. A custom-made apparatus designed to measure contractile force of muscle tissue was used for these [24]. Fresh PSS was added to the 50 mL volume solution reservoir of the set-up and allowed to equilibrate to 37 °C (heated by a circulating water bath). The solution pump was set to allow the PSS to flow through the set-up at a slow and steady rate. A preparation bath volume of 400 µl was continuously circulated at approximately 10 refreshments per minute. Myometrium strips were mounted in the apparatus between two hooks, with one of the hooks attached to a force transducer (KG7, World Precision Instruments, Sarasota, Florida). The strips were trimmed, if necessary, to be no more than 5 mm in length in the pre-stretched state. The initial resting tension was adjusted to 0 mN/mm2. The myometrium was slowly stretched to optimal length with a micromanipulator until the resting tension was between 1.5–2.0 mN/mm2. Once optimal length and tension were achieved, the length, width, and thickness were recorded in custom-written LabView™ software (National Instruments, Austin, TX). The muscles were allowed to stabilize and begin spontaneously contracting approximately 1.5–2 h after mounting. After the first contraction, the specimens were allowed to stabilize for 1 h to establish a baseline. Myometrial strips that did not exhibit spontaneous contractions within 2 h after mounting in the device were excluded from further analysis.
Oxytocin stock solutions were prepared at 10 mM in PSS and a dose–response study was initiated by treating tissues with escalating doses of oxytocin (10–10 to 10–8 M). Recordings of oxytocin-induced tension were made at each concentration at 15-min intervals. At the conclusion of the oxytocin dose–response protocol, the reservoir was replaced with pre-heated high K+ solution to confirm contractile integrity.
Contractility Analysis
Contractility data was recorded with a custom-made program in LabView. Data analysis was conducted using Microsoft Excel and GraphPad Prism (version 9.4.0). We recorded contraction frequency defined as the number of contractions within 15 min. Four additional kinetic parameters were assessed: time to peak tension (TTP, s), time to achieve half maximal tension (s), total duration of contraction (Total Duration of Contractions, s), and force per cross-sectional area (mN/mm2). Baseline contractility data prior to exposure to oxytocin was compared between the normal-weight and obese groups using the Student’s t test. Oxytocin dose–response curves were then created for each contraction parameter using data collected at baseline and with each increasing oxytocin concentration. Two-way ANOVA with Šidák’s multiple comparison test was used to compare the dose response curves in the two groups. A two-tailed p-value < 0.05 was considered significant.
RNA Extraction and qRT-PCR
Frozen myometrial specimens were thawed, dissected, and placed into RNase-free 1.5- ml microfuge tubes containing 1 ml of TRIzol™ reagent (ThermoFisher) and high-impact glass 1.5 mm beads. Samples were homogenized with a single 180-s round of tissue disruption at 50 Hz using a BeadBug™ 3 microfuge tissue homogenizer (Southern Labware, Cumming, GA). Following addition of chloroform and centrifugation, the aqueous phase was removed and added to an equal volume of 100% ethanol. The mixture was applied to a miRNeasy spin column (Qiagen, Valencia, CA, United States) and processed according to the manufacturer’s protocol. RNA concentrations were quantified using a Nanodrop 2000 spectrophotometer (ThermoFisher, Hudson, NH, United States). Complementary DNA (cDNA) was prepared using oligo(dT)12–18 primers with SuperScript III Reverse Transcriptase (Life Technologies, Grand Island, NY, United States). Quantitative PCR was performed using a LightCycler 480 II System (Roche Applied Science, Indianapolis, IN, United States) and the following TaqMan primer/probe sets (Applied Biosystems, Foster City, CA, United States): OXTR, PGFR, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene used for normalization of samples. Assays were run in duplicate and the relative amount of mRNA in each sample was calculated as cycle threshold (CT) values for each gene and normalized to CT values obtained from the housekeeping gene, GAPDH, using the 2−∆∆CT method.
Protein Extraction and Western Blot Analysis
Frozen myometrial specimens were thawed and homogenized in the BeadBug™ 3 tissue disrupter described above in 1 ml of RIPA buffer (25 mM tris (hydroxymethyl) aminomethane hydrochloride, Tris–HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, DOC, 0.1% sodium dodecylsulfate, SDS) containing protease inhibitor cocktail and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). Total protein was determined using the Bradford assay [25] (Biorad protein assay reagent) using BSA as standard. Samples (40 μg/lane) were fractionated by SDS-PAGE on 4–20% sodium dodecylsulfate-polyacrylamide (SDS-PAGE) NuPAGE™ gels (Invitrogen) and transferred to nitrocellulose membranes using the iBlot™ semi-dry transfer apparatus and iBlot™ Transfer Stacks (Invitrogen). After blocking overnight in 5% non-fat dry milk/Tris-buffered saline with 0.2% Tween-20 (TBST), the blots were probed with antibodies directed against: oxytocin receptor, OXTR; prostaglandin F2α receptor, FP; and glyceraldehyde 3-phosphate dehydrogenase, GAPDH, a housekeeping gene used for normalization of samples. Blots were developed with Clarity™ ECL western blot chemiluminescence reagent (Biorad) and immunoreactive proteins visualized using the Chemidoc™ MP Gel Imaging System (Biorad).
Receptor Expression Statistical Analysis
Data regarding OXTR and FP gene and protein expression within the myometrial samples are presented as median values with interquartile ranges [IQR]. Grubbs’ test was used to detect outliers and significant outliers were excluded from final analysis. Differences between the normal-weight and obese groups were evaluated using the Mann Whiney U test. The analysis was performed using Prism 10 (GraphPad Software Inc, La Jolla, California).
Sample Size Calculation
Our preliminary data found that the mean concentration with standard deviation of OXTR gene expression normalized to the housekeeping gene in myometrial tissue from normal-weight patients was 13.2 ± 7.0. Using a two-sided test and assuming alpha of 0.05, we would need to enroll 70 pregnant individuals in a 2:1 ratio of obese to normal-weight participants to detect a 33% difference expression of OXTR receptor with 85% power.
Results
Seventy-three pregnant individuals, presenting for scheduled cesarean delivery at ≥ 37 weeks’ gestation, were enrolled in the study. Of these participants, 49 (67.1%) had a pre-pregnancy BMI ≥ 30 kg/m2, while 24 participants (32.4%) had a pre-pregnancy BMI < 25.0 kg/m2. One myometrial tissue sample from the BMI < 25 kg/m2 had insufficient quantity to perform receptor expression experiments and was used for the contractility study only. Contractility experiments were only performed in a subset of the total sample. Reasons for this included failure of the myometrial tissue to spontaneously contract, inadequate quantity of the myometrial sample, and/or inability to perform the contractility studies within an appropriate time from sample collection. In total, contractility studies were performed using myometrial samples from 16 participants in the obese group and 9 from the normal-weight group.
| Characteristic | BMI ≥ 30 kg/m(= 49)2n | BMI < 25 kg/m(= 24)2n |
|---|---|---|
| Maternal age (years) | 33.4 ± 5.1 | 31.9 ± 4.9 |
| Parity | ||
| 1 ≥ 2 | 3 (6.1) 30 (61.2) 16 (32.7) | 4 (16.7) 12 (50.0) 8 (33.3) |
| Race/ethnicity | ||
| Hispanic Non-Hispanic Black Non-Hispanic White None of the above | 2 (4.2) 10 (20.8) 34 (70.8) 2 (4.2) | 1 (4.4) 3 (13.0) 17 (73.9) 2 (8.7) |
| Gestational age | 39.0 (38.0, 39.3) | 39.1 (39.0, 39.4) |
| Weight gain during pregnancy (kg)a | 10.9 (6.3, 15.9) | 15.2 (13.6, 19.0) |
| Delivery BMI (kg/m)2a | 41.1 (36.9, 49.1) | 27.5 (25.9, 29.2) |
| Indication for cesarean | ||
| Prior cesareanMalpresentationOtherb | 42 (85.7) 3 (6.1) 4 (8.2) | 19 (79.2) 4 (16.7) 1 (4.17) |
| Infant birthweight (grams) | 3470 (3120, 3910) | 3150 (2890, 4340) |
Contractility Studies
Representative tracing of spontaneous and oxytocin-induced contractions from participants with () normal BMI (24.6 kg/m) and () obese BMI (51.7 kg/m). Samples spontaneously contracted and oxytocin was serially added in 15-min increments a b 2 2
a-e. Comparison of contraction parameters with increasing concentrations of oxytocin in myometrium from normal-weight (BMI < 25 kg/m) and obese (BMI ≥ 30 kg/m) participants.Contraction Frequency,> 0.05; normal-weight= 9, obese= 15 at 10and 10M,= 14 at 10and 10M,= 16 at 10M oxytocin.Average duration of contractions (s),> 0.05; normal-weight= 9, obese= 15 at 10and 10M,= 14 at 10and 10M,= 13 at 10M oxytocin.Average maximal force of contractions (mN/mm,< 0.05 for normal-weight samples at 10-10M oxytocin compared to baseline value of normal-weight sample per 2-way ANOVA with Šídák’s multiple comparison test; normal-weight= 9, obese= 9 at 10and 10M,= 8 at 10and 10M,= 7 at 10M oxytocin.Percentage of baseline force, contractions (mN/mm,< 0.05 for normal-weight samples at 10-10M oxytocin compared to baseline value of normal-weight sample per 2-way ANOVA with Šídák’s multiple comparison test; normal-weight= 9, obese= 9 at 10and 10M,= 8 at 10and 10M,= 7 at 10M oxytocin.Average time-to-peak tension (s),> 0.05; normal-weight= 9, obese= 13 at 10M and 10M,= 12 at 10and 10M,= 11 at 10M oxytocin.Average time-to-half-maximal tension (s),> 0.05; normal-weight= 9, obese= 13 at 10M and 10M,= 12 at 10and 10M,= 11 at 10. Normal-weight and obese samples at each dose of oxytocin were compared to themselves at baseline as well as to the opposing group. Doses administered in 15-min increments. Data presented as average values at each dose with SEM error bars 2 2 –10 –9 –9.5 –8.5 –8 –10 –9 –9.5 –8.5 –8 2 –10 –8 –10 –9 –9.5 –8 –8.5 2 –10 –8 –10 –9 –9.5 –8 –8.5 –10 –9 –9.5 –8 –8 –10 –9 –9.5 –8 –8.5 a b c d e f p n n n n p n n n n p n n n n p n n n n p n n n n p n n n n
| Parameter | BMI ≥ 30 kg/m(= 16)2n | BMI < 25 kg/m(= 9)2n | p |
|---|---|---|---|
| Contraction frequency (n/15 min) | 4.5 ± 0.6 | 4.3 ± 0.8 | 0.86 |
| Time to peak tension (TTP, s) | 31.1 ± 4.5 | 26.1 ± 4.5 | 0.46 |
| Time to half maximal tension (s) | 22.0 ± 3.1 | 21.1 ± 2.6 | 0.84 |
| Total duration (s) | 174.9 ± 26.5 | 165.9 ± 35.4 | 0.84 |
| Maximum force (mN/mm)2 | 16.3 ± 4.4 | 11.7 ± 3.5 | 0.42 |
Expression of Oxytocin and Prostaglandin FReceptors in Myometrium in Normal-Weight and Obese Groups 2α
![Myometrial OXTR () and FP gene () expression in normal-weight and obese pregnant individuals at term. Cycle threshold (CT) values were calculated for each gene and normalized to CT values obtained from the housekeeping gene, GAPDH, using the 2method. Data are reported as median [IQR].OXTR:= 24 normal-weight,= 49 obese. FP:= 24 normal-weight,= 48 obese a b −∆∆CT n n n n](https://europepmc.org/articles/PMC11438831/bin/43032_2024_1661_Fig3_HTML.jpg.jpg "Click to view full size")
Myometrial OXTR () and FP gene () expression in normal-weight and obese pregnant individuals at term. Cycle threshold (CT) values were calculated for each gene and normalized to CT values obtained from the housekeeping gene, GAPDH, using the 2method. Data are reported as median [IQR].OXTR:= 24 normal-weight,= 49 obese. FP:= 24 normal-weight,= 48 obese a b −∆∆CT n n n n
![Myometrial OXTR () and FP () protein expression in normal-weight and obese pregnant individuals at term. Data are reported as median [IQR]. OXTR:= 22 normal-weight,= 48 obese. PGFR:= 21 normal-weight,= 46 obese a b n n n n](https://europepmc.org/articles/PMC11438831/bin/43032_2024_1661_Fig4_HTML.jpg.jpg "Click to view full size")
Myometrial OXTR () and FP () protein expression in normal-weight and obese pregnant individuals at term. Data are reported as median [IQR]. OXTR:= 22 normal-weight,= 48 obese. PGFR:= 21 normal-weight,= 46 obese a b n n n n
Representative western blots.Myometrial samples probed with antibodies directed against oxytocin receptor (OXTR).Myometrial samples probed with antibodies against prostaglandin receptor (FP). “Ob” represents a sample from an individual with obesity and “Non-Ob” represents a sample from a normal-weight individual a b
Discussion
In our prospective cohort study, we found that spontaneous and oxytocin-induced contractility was similar in term myometrial samples from pregnant individuals with obesity compared to those with normal BMI. Additionally, there were no differences in expression of either oxytocin or prostaglandin F2α receptors, which are key components within the signaling pathways leading to myometrial contractions in pregnancy.
The role of maternal obesity in dysfunctional labor and increased risk of cesarean delivery is a prominent issue in obstetrics, but the mechanisms that underpin the clinical observation are not understood [8, 16, 26]. One way to address the issue of myometrial function in the context of obesity is to measure uterine muscle contractility using a well-established ex vivo model [23]. In this system, physiological parameters (e.g., contraction frequency, duration and force) can be measured using small segments of myometrium isolated from pregnant individuals of various pre-pregnancy BMI values to ascertain whether maternal adiposity influences contractility. The main findings of our study indicate that myometrial sample contractility, including contraction frequency, duration and generated force, do not differ significantly between obese and normal-weight individuals, using pre-pregnancy BMI as the measure of adiposity. These results are consistent with those reported by Higgins et al. in a larger cohort of individuals, in which they found no significant association between maternal BMI and measures of contractility in myometrial samples obtained at time of cesarean [19]. Other investigators have observed differences in myometrial contractility in obese and non-obese individuals using similar laboratory techniques, but their results have been inconsistent. For example, one group found higher BMI was associated with lower contraction force and frequency [16], while another group found that higher maternal BMI was associated with increased myometrial contractile force but no difference in frequency [17]. We also expanded upon the work of other researchers by evaluating additional muscle kinetic parameters including time to peak tension and time to half-maximal tension, albeit no differences were observed.
To better understand the potential biomolecular mechanisms by which obesity could affect myometrial function, we investigated myometrial gene and protein expression of OXTR and FP receptor. Our findings suggest that maternal BMI is not associated with differential myometrial expression of OXTR. This supports findings from Grotegut et al. whose work also demonstrated no association between maternal BMI and OXTR expression [22]. Activation of OXTR in myometrial cells and other gestational tissues induces a signaling cascade that ultimately leads to the generation of myometrial contractions. One of the downstream effects of oxytocin binding to its receptor is the formation of prostaglandins. Prostaglandins, such as PGF2α, bind to prostaglandin receptor, FP, on myometrial cells to promote myometrial contractility [20]. In our study, myometrial samples from pregnant individuals with obesity at term had significantly reduced FP gene expression compared to myometrial samples from normal-weight individuals, yet we detected no difference in the protein expression of the FP. Further research is needed to better define this possible association. To our knowledge, this is the first study to investigate the association between maternal BMI and FP expression in the myometrium in pregnancy.
The present investigation has both strengths and limitations. First, we recruited only non-laboring individuals avoiding previous myometrial activation in vivo and included only samples that exhibited spontaneous and K+-activated contractile activity once placed in the ex vivo system. Second, we attempted to correlate contractile activity with the expression of two major uterotonic receptor systems, OXTR [20] and FP [27]. Another strength was the high proportion of participants with obesity in our study. Similar studies that have assessed the association between maternal BMI and uterine contractility have included a relatively small proportion of patients with obesity. For example, Higgins et al. performed a study with samples from 85 pregnant individuals but only 22 (25.9%) had a BMI ≥ 30 kg/m2 and only 3 had class III obesity (BMI ≥ 40 kg/m2) [19], whereas the median BMI in our obese group was 37.9 kg/m2.
A limitation of our study is the small sample size, particularly with regards to the performance of contractility experiments, which were only performed in a third of the total samples due to availability of research team member with the expertise to perform the studies in the appropriate timeframe as well as adequacy of the samples. Moreover, there was considerable variability in both contractile activity and expression of relevant receptors (OXTR and FP) that are the initiators of uterotonic signaling in the specimens. The fact that only small segments of myometrium from a single region of the uterus are used for the ex vivo contractility measurements make it a formidable challenge to ascertain a thorough picture of the role of obesity in uterine activity. Samples were also collected from individuals undergoing pre-labor cesarean delivery, thus may not adequately reflect differences in myometrial function during labor. Ideally, measuring uterine activity in vivo would be preferable, but this is technically challenging in humans.
The decision to use pre-pregnancy BMI rather than BMI at time of delivery is also controversial but is consistent with approaches used by other investigators who have evaluated the influence of BMI on in vitro myometrial contractility studies in pregnancy [16, 18, 19]. A leading theory related to obesity and labor dysfunction is that metabolic and hormonal factors related to adiposity influence myometrial contractility [28]. As it is possible that individuals with normal pre-pregnancy BMI (18.5–24.9 kg/m2) can have a BMI categorized as overweight or even obese with recommended weight gain, pre-pregnancy BMI may better identify individuals with metabolic and hormonal phenotypes characteristic of obesity than delivery BMI. An evaluation of the interaction between pre-pregnancy BMI and gestational weight gain on myometrial function would of great interest in the future but would require a larger study.
Conclusion
Our study demonstrated no association between maternal obesity and intrinsic myometrial contractility. These results suggest alternative mechanisms for the higher rates of labor dysfunction observed clinically in individuals with obesity. Additionally, our results show that differences in oxytocin receptor expression are also unlikely to explain these clinical observations. More research to expand our understanding of the mechanisms underlying the relationship between maternal BMI and labor progress is clearly needed.